Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps his Department is taking to ensure NHS Trusts comply with NICE CG143 and national sickle cell clinical standards in the management of acute sickle cell crises, particularly in relation to timely escalation of analgesia and adherence to individual care plans.

The NHS England Sickle Cell and Thalassaemia Improvement Programme aims to address health inequalities through targeted interventions. A key priority for the programme has been supporting National Health Service trusts in the management of acute sickle cell crises.

The programme has rolled out seven sickle cell Emergency Department Bypass Accelerator Sites to provide rapid access to pain relief for uncomplicated vaso-occlusion crises. The sites across the country are mainly in areas with a high prevalence of sickle cell, with four based in London and three in the North of England. The accelerator sites operate a 24/7 service, providing patients with direct access to specialist sickle cell care, either through self-referral, ambulance pathways, or transfer between wards. An evaluation of the effectiveness of the units is being carried out by the National Institute for Health and Care Research with early indications suggesting significant improvements in time to analgesia as per the National Institute for Health and Care Excellence CG143 guideline. A full report is expected in Quarter four of 2026.

In 2024, NHS England funded a programme of work to ensure that all patients with sickle cell in London and Greater Manchester have access to a personalised digital care plan, with an ambition to expand to other regions when the technology becomes available.